((自动化翻译由路透提供,请见免责声明 ))
路透12月30日 - Sangamo Therapeutics 周一表示,在共同开发伙伴辉瑞 终止协议后,该公司将重新获得其A型血友病基因疗法的全部权利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.